Nowadays, both the discovery of imatinib mesylate (IM) as the first designed BCR::ABL1 tyrosine kinase inhibitor (TKI), as well as research performed concerning second (dasatinib, nilotinib and bosutinib) and third-generation (ponatinib) TKIs, has dramatically enhanced the survival expectancy among CML patients [7]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.